MedCity News August 27, 2025
Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.
Note: This is the third article of a three-part series.
Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and committees overseeing hospital and payer formularies. It influences how much pharmaceutical companies can charge for their drugs and which ones are covered by payers. RWE also shows how treatments perform in routine clinical settings. It includes measurable improvements in patient outcomes, enhanced quality of life, and reductions in healthcare costs. This allows companies to make more informed...
Today's Sponsors
Today's Sponsor